On diabetic foot, wound healing, amputation prevention, and the merger of consumer tech with medical devices
Senneville and Lipsky return with a measured rejoinder in Clinical Infectious Diseases (April 2026), arguing that the Lagrand trial shows the absence of evidence of superiority — not definitive equivalence — between ulcer-bed and bone biopsy for guiding antibiotic therapy in diabetic foot osteomyelitis.
Diabetic foot osteomyelitis (DFO) is a formidable challenge in limb preservation, often leading to major amputations and significant morbidity. Systemic antibiotic treatments are fraught with limitations—poor tissue penetration due to peripheral arterial disease, risks of systemic toxicity, and antibiotic resistance. But what if we could deliver antibiotics exactly where they are needed most? A groundbreaking randomized controlled... Continue Reading →
This from our sister unit at Zurich's The Balgrist along with one of our longest-standing SALSAmigos, Prof. Ben Lipsky. Abstract Aim To retrospectively evaluate clinical and microbiological outcomes after combined surgical and medical therapy for diabetic foot infections (DFIs), stratifying between the empirical versus the targeted nature, and between an empirical broad versus a narrow-spectrum,... Continue Reading →
